Alector, Inc. Overview
Pro stress-test →Alector is a late-stage clinical biotechnology company developing therapies focused on counteracting the devastating progression of neurodegenerative diseases. The company combines a proprietary blood-brain barrier delivery platform with multiple clinical-stage programs targeting unmet needs in diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.
Strategic Profile
Pro stress-test →The company advances its pipeline leveraging its proprietary Alector Brain Carrier (ABC) platform, which enhances drug delivery to the brain and is designed to enable peripheral dosing adaptable across multiple drug modalities including antibodies, enzymes, and siRNA. Alector has a strategic collaboration agreement with GlaxoSmithKline for the development and commercialization of progranulin-elevating monoclonal antibodies.
Competitive Landscape
Pro stress-test →Alector faces competition from larger biotech firms which increases risks of dilution and challenges in attracting resources. The company competes in the neurodegenerative disease space against other clinical-stage biotech companies pursuing Alzheimer's, Parkinson's, and FTD therapies. Alector's ABC platform differentiation provides a competitive advantage in brain delivery mechanisms.
Industry Context
Alector, Inc. operates in Pharmaceutical Biotechnology - Neurodegenerative Diseases.
Key facts
Founded: 2013 · Headquarters: South San Francisco, California · Revenue: $69M · Market cap: $172M